Antibody Targeting of “Steady-State” Dendritic Cells Induces Tolerance Mediated by Regulatory T Cells by Karsten Mahnke et al.
February 2016 | Volume 7 | Article 631
Review
published: 23 February 2016
doi: 10.3389/fimmu.2016.00063
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Helmut Jonuleit, 
Johannes Gutenberg-University 
Mainz, Germany
Reviewed by: 
Ciriaco A. Piccirillo, 
McGill University, Canada 
Urszula Krzych, 
Walter Reed Army Institute of 
Research, USA
*Correspondence:
Karsten Mahnke  
karsten.mahnke@med. 
uni-heidelberg.de
Specialty section: 
This article was submitted to 
Immunotherapies and Vaccines, 
a section of the journal 
Frontiers in Immunology
Received: 29 October 2015
Accepted: 08 February 2016
Published: 23 February 2016
Citation: 
Mahnke K, Ring S and Enk AH (2016) 
Antibody Targeting of “Steady-State” 
Dendritic Cells Induces Tolerance 
Mediated by Regulatory T Cells. 
Front. Immunol. 7:63. 
doi: 10.3389/fimmu.2016.00063
Antibody Targeting of “Steady-State” 
Dendritic Cells induces Tolerance 
Mediated by Regulatory T Cells
Karsten Mahnke* , Sabine Ring and Alexander H. Enk
University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany
Dendritic cells (DCs) are often defined as pivotal inducers of immunity, but these proin-
flammatory properties only develop after stimulation or ex vivo manipulation of DCs. 
Under non-inflammatory conditions in vivo, DCs are embedded into a tissue environment 
and encounter a plethora of self-antigens derived from apoptotic material. This material 
is transported to secondary lymphoid organs. As DCs maintain their non-activated 
phenotype in a sterile tissue environment, interaction with T cells will induce rather reg-
ulatory T cells than effector T cells. Thus, DCs are not only inducers of immunity but are 
also critical for maintenance of peripheral tolerance. Therapeutically, intervention for the 
induction of long-lasting tolerance in several autoimmune conditions may therefore be 
possible by manipulating DC activation and/or targeting of DCs in their “natural” tissue 
environment.
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iNTRODUCTiON
Mature dendritic cells (DCs) are perfectly equipped with MHC class II–peptide complexes and T cell 
interacting molecules (immune stimulatory and immune regulatory ones) to regulate T cell activa-
tion and differentiation in secondary lymphoid organs. The DCs act as sentinels in the periphery of 
the body where they take up antigens and sample the cellular environment. From here, antigens are 
transported into secondary lymphoid organs, and the subsequent interaction with T cells is critical 
for induction of immunity as well as for induction of tolerance. Initial investigations established 
DCs as pivotal inducers of immunity but with more molecules discovered on the surface of DCs and 
refined immunological methods, a role in the induction of regulatory T cells (Treg) became clear (1).
The initial experiments on DC functions involved the isolation of DCs from tissues and the ex 
vivo generation from either bone marrow cells (mouse) or monocytes (human). But these in vitro 
methods inherently stimulate and activate the developing DCs and when analyzed in T cell stimula-
tion assays, activating capacity was recorded for most DC types.
In contrast to in vitro cultures, in vivo DCs are embedded in a tissue and additional activating 
stimuli, i.e., TLR ligands and/or trauma have to be applied to DCs in situ in order to mature them 
and to stimulate their proinflammatory functions. This maturation process is fast (approx. 6 h) and 
effective (2). It induces migration to secondary lymphoid organs and surface expression of MHC 
class II and T cell costimulatory molecules (3). Therefore, approaches to isolate naïve, non-activated 
DC directly from tissues is nearly impossible, as manipulation provides enough stimuli to trigger 
maturation.
FiGURe 1 | The two different faces of DCs. Depending on the activation status and/or antigen delivery immunity or Treg induction ensues. During tissue 
disruption or infection, antigens are delivered to DCs together with activating signals. This leads to activation of DCs marked by the production of proinflammatory 
cytokines and expression of T cell costimulatory molecules. During sterile, i.e., steady-state conditions, transportation of antigens to DCs in situ by DC-specific 
antibodies leads to uptake and antigen presentation by DCs without activating them. In the absence of T cell costimulatory molecules and further support by soluble 
mediators, such as TGF-β or IL-10, Treg are generated by “steady-state” DCs.
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IN VIVO TARGeTiNG OF ANTiGeNS TO 
iMMATURe DCs iNDUCe TReG
A fundamentally different approach from isolating DCs and 
pulsing them with respective antigens is the technique to load 
DCs in vivo by antibody targeting. This approach, so far mostly 
tested in animal models, mimics the in  situ situation better. 
Here, DCs remain embedded into a tissue environment, and no 
further stimuli, such as trauma and/or infection, are present. In 
this sterile environment, the antigen is delivered by binding to a 
DC-specific antigen-uptake receptor. One of the first receptors 
used in this approach is the DEC205 receptor (4, 5). DEC205 is 
a lectin-like receptor and is closely related to the macrophage-
mannose receptor. DEC205 recycles through late endosomal 
MHC class II+ compartment and effectively promotes antigen 
presentation by DCs (6). Therefore, techniques were developed 
to couple antigens to DEC205-specific antibodies and to inject 
these conjugates into animals (Figure 1).
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In initial experiments model antigens, such as hen egg lysozyme 
or ovalbumin, which are frequently used in immunology, were 
coupled to anti-DEC205 antibodies. In these experiments it 
was proven that anti-DEC coupled antigens (anti-DEC:antigen) 
targeted DCs in situ and that the antigens were indeed taken up 
by the DCs (7–9). This process was highly specific as uptake of 
anti-DEC:antigen conjugates by Fc receptor expressing cells, such 
as macrophages, B cells, or granulocytes, was negligible. When 
anti-DEC:antigen conjugates were injected into animals without 
further adjuvant the DC phenotype remained non-activated and 
T cell costimulatory molecules, such as B7.1 and B7.2, showed 
expression levels comparable to those obtained in DCs from 
control mice. However, the steady-state DCs were not immu-
nologically inactive, because analysis of antigen-specific T cell 
populations in injected mice revealed increased numbers of Treg. 
These T cells expressed the bona fide Treg markers CD4, CD25, 
IL-10, and FoxP3, and were able to suppress proliferation of CD4+ 
T cells in vivo (8, 10). Thus, antigen presentation by steady-state 
DCs in vivo induces Treg, which offers the possibility to provide 
a tool for tolerogenic cell therapy in humans.
ANTiBODY TARGeTiNG TO DC AS 
THeRAPeUTiC TOOL iN AUTOiMMUNe 
DiSeASeS
To assess the possibilities of DEC targeting in therapeutic set-
tings, self-antigens were coupled to anti-DEC205 antibodies 
and conjugates were tested in respective animal models. For 
instance, anti-DEC205 targeting and Treg induction thereof was 
tested in a transgenic mouse model for diabetes. In this model, 
transgenic mice express hemagglutinin (HA) under control of 
the RIP promoter in pancreatic islets and develop insulinitis 
(and finally diabetes) upon transfer of HA-specific T cells. When 
anti-DEC:HA conjugates were used in this model, insulinitis was 
prevented and diabetes did not develop (11).
Also in another autoimmune model, the experimental allergic 
encephalitis (EAE), which serves as model for multiple sclerosis, 
anti-DEC:antigen targeting lead to strong amelioration of the dis-
ease. Here, the naturally occurring autoantigen MOG was fused 
to DEC205-specific single chain fragment variables and mice 
were treated before and during EAE induction. It was found that 
IL-10 producing CD4/CD25/FoxP3+ Treg were induced, which 
prevented outbreak of EAE when animal were “tolerized” by 
anti-DEC:MOG before induction of the disease (12). Moreover, 
even when anti-DEC:MOG treatment was started after onset of 
EAE symptoms, a significant amelioration of the disease could 
be observed. Finally, targeting of the cartilage proteoglycan to 
DEC205+ DCs by means of antibody:antigen conjugates lead to 
prevention of autoimmune arthritis (13). In summary, these data 
establish DC targeting via DEC205 as an effective strategy to toler-
ize against autoantigens in order to protect against autoimmunity.
The DEC205 receptor is in particular suited for DC targeting, 
as it not only binds antigens to DCs, but also acts as a prototype 
antigen receptor that actively delivers potential ligands to MHC 
class II+ compartments. But recently also other surface molecules 
for DC targeting have been defined on several subsets of DCs. But 
most of them (e.g., DC-SIGN and CD40) are used for induction of 
immunity, as they may also possess DC-activating capacity (14). 
But for CLEC9A mediated targeting, both Treg-inducing and 
immune stimulatory effects have been described (15–17), and 
it remains unclear which co-factors and/or differentiation pat-
terns of DCs are involved in regulating these opposite functions. 
However, some novel candidates have been shown to be able to 
induce Treg and to lead to tolerance. Among them are CD103, 
langerin (CD207) (18), triggering receptor on monocytic-like 
cells (Treml)-4, and Clec4A (19). All are expressed by DCs in 
varying degrees. However, the most effective DC populations for 
Treg induction were positive for CD103 and CD207. Interestingly, 
these molecules are predominantly expressed by tissue residing 
DCs (e.g., skin and/or gut), which are highly migratory and 
enter the secondary lymphoid organs on their normal trafficking 
routes (20).
STEADY-STATE DCs ARe PRONe TO 
iNDUCe TReG-MeDiATeD TOLeRANCe
Irrespective of the specificity and the signaling capacity of the 
antibodies used for targeting, one common denominator for Treg 
induction by DCs after antibody targeting is their “steady state.” 
This became clear when the same antibody:antigen complexes, 
which were successfully used for tolerance induction, were 
injected together with DC-activating stimuli. For instance, when 
anti-DEC205 antibodies were coupled to tumor antigens, they 
were able to induce robust anti-tumor immunity when applied 
together with TLR ligands (21). Similar results were obtained 
with CLEC9A, which when applied under DC-activating condi-
tions, induces strong humoral and cellular Th1 immunity (16, 
17). Therefore, the activation status of the DCs may be critical for 
decision making on whether tolerance, or immunity ensues after 
DC–T cell interaction in secondary lymphoid organs.
These opposed functions of otherwise similar DC subsets (as 
defined by surface marker expression) led to a conceptual view 
that not particular subsets of DCs but rather non-activated or 
steady-state DCs are involved in generating Treg and tolerance. 
Similar to their function as immune stimulators, DCs act as 
sentinels in the periphery of the body (22). In the absence of 
inflammation or tissue injury, DCs are constantly exposed to 
self-proteins. These proteins are taken up and transported by 
DCs to secondary lymphoid organs. But in contrast to foreign and 
potentially dangerous antigens, the self-antigens are presented in 
a tolerogenic fashion to induce Treg and pave the way for further 
suppressive mechanisms. Altogether, this may be a crucial process 
to maintain peripheral tolerance (23).
In support of this notion, it has been reported that in periph-
eral tissues, DCs engulf self-antigens provided by microvesicles, 
exosomes (24, 25), and detritus of epithelial cells lining the gut 
and lung (26, 27). These antigens are transported and presented to 
T cells in the draining lymph nodes (28). In particular, apoptotic 
cells contain a collection of self-antigens and immunity against 
those antigens would be fatal. Therefore, further safeguards to 
prevent DC activation and immunity are in place. In case of apop-
totic material, specialized receptors, such as CD36 and αvβ3/αvβ5 
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integrins expressed by DCs, detect components of apoptotic cells 
and induce intracellular signaling events to prevent maturation 
and cytokine production (29, 30). In more detailed studies, the 
molecules Gas and Protein 6, expressed by dying cells are recog-
nized by MerTK, leading to signaling via the rather inhibitory 
STAT3 pathway and simultaneously inhibiting NFkB activation 
(31). In summary, apoptotic material will keep DCs non-
activated and presentation of the “self-derived” apoptotic cargo 
will not activate effector T cells. Moreover, the steady-state DCs 
will induce CD4+CD25+ Treg, which in turn will now suppress 
potentially self-reactive T cells.
This conceptual view requires a constant flow of non-activated 
DCs from the periphery to secondary lymphoid organs for the 
upkeep of Treg activation. If this trafficking is compromised, 
autoimmunity will develop. That has been demonstrated in a 
transgenic mouse model, where skin derived DCs are constantly 
activated by genetic manipulation. Here, severe autoimmunity to 
skin tissue is induced (32). Moreover, in humans, the incidence 
of the autoimmune disease systemic lupus erythematosus (SLE) 
is strongly correlated to a chronically activated phenotype of DCs 
(33). On the whole, these data suggest that DCs constantly sample 
the repertoire of peripheral proteins and are an effective source of 
“self-peptide–MHC” complexes. By presenting these complexes 
in the steady state, DCs induce Treg and thus suppress potentially 
self-reactive T cells.
DC NOT ONLY iNDUCe TReG BUT ALSO 
LiMiT THeiR NUMBeRS BY CONveRTiNG 
THeM iNTO eFFeCTORS
All these data clearly demonstrate that experimentally modified 
and/or specialized DC subsets exist that are able to induce Treg. 
However, Treg are not always stable in phenotype and function, as 
they can convert into proinflammatory cells and loose their sup-
pressive potential. In vivo, during the development of type-1 and 
type-2 responses, Treg are exposed to a variety of cytokines and in 
this process, DCs play a role in driving the conversion of Treg into 
Th17-like cells either directly or indirectly. A rather indirect and 
cytokine mediated pathway involves IL-6, which can be secreted 
by activated DCs. This IL-6 secretion by DCs may contribute 
to Treg conversion as natural Treg develop into IL-17+, IFNγ+ 
proinflammatory cells after treatment with IL-6 in vitro (34, 35).
A direct mechanism by which DCs are involved in converting 
mouse CD25+Foxp3+ Treg into a proinflammatory cell type is 
demonstrated by dectin-1. This C-type lectin receptor is normally 
involved in fungal recognition. But in cocultures of Treg with 
DCs that have selectively been activated via dectin-1, IL-23 is 
produced. This leads to conversion of Treg into Th17-like effec-
tor T cells, characterized by the expression of ROR-γt and the 
production of IL-17 (36).
In addition to dectin-1, which is rather an antigen-uptake 
molecule and may therefore signal intracellular after uptake of 
antigens, surface molecules, such as the T-cell immunoglobalin 
mucin (TIM-1), may have direct outside-in signaling capacities 
to turn down Treg induction by DCs by means of Treg conver-
sion. For TIM-1, it has been shown that a high-avidity/agonistic 
anti-Tim-1 antibody enhances the immunogenic function of 
DCs, leading to decreased suppressive function of Treg. At the 
same time, substantially increased conversion of Treg into proin-
flammatory IL-17+ T cells was observed (37).
Likewise, CD18 seems also to be involved in regulating 
DC-mediated Treg conversion into proinflammatory T cells (38). 
In a CD18-deficient mouse model, enhanced numbers of Th17 
cells were observed resulting in a psoriasis-like phenotype. These 
data are backed by clinical observations in humans, showing that 
patients with LAD syndrome (leukocytes do not express func-
tional CD18 in LAD patients) have both elevated levels of Th17 
cell and psoriasiform skin disease. Further experiments revealed 
that this accelerated conversion of Treg into Th17 cells was due to 
an inadequate DC-Treg interaction via CD18 because blockade 
of CD18 interactions between DCs and Treg in vitro lead to rapid 
generation of IL-17+ “ex”-Treg.
However, not only the stability of Treg is influenced by DCs 
and their respective cytokine environment but also their induc-
tion is affected by the context of cytokines and/or pathogens. By 
broadening the concept that immature DCs are prone to induce 
Treg, it is conceivable that fully activated and mature DCs induce 
effectors and may even hamper Treg generation.
For instance, retinoic acid (RA) has been shown to promote 
conversion of naïve T cells into Treg cells, presumably by acting 
on DCs and augmenting TGF-β. Henceforth, studies have been 
undertaken to block RA receptors by an antagonist (RARi). RARi 
significantly suppressed TGF-β and IL-10, and enhanced IL-12 
production by DC in a tumor model. This protective effect was 
associated with significant reduction in tumor-infiltrating FoxP3+ 
and IL-10+ Treg cells, and a corresponding increase in tumor-
infiltrating CD4+ and CD8+ T cells that secreted IFN-γ (39).
Also, vigorously enhanced expression of T-cell costimulatory 
molecules by DCs provides a means by which Treg activation is 
suppressed. In the study of Pen et al. (40), DCs were transfected 
with constitutively active TLR4, CD40 ligand, and the costimu-
latory molecule CD70. These DCs could partly alleviate Treg 
inhibition of CD8+ T cells, which was further accompanied by 
a decrease in CD27 and CD25 expression on Treg. Moreover, an 
increase in the expression of T-bet and secretion of IFN-γ, tumor 
necrosis factor (TNF)-α, and IL-10 was recorded, suggesting a 
shift of the Treg phenotype toward a Th1 phenotype.
Finally, even without molecular transfection approaches, 
CpG-ODN-stimulated DCs exhibited pivotal proinflammatory 
functions, as in a Leishmania donovani model intracellular 
parasitic growth was abolished by these CpG-stimulated DCs 
(41). Alongside, it was observed that DC vaccination resulted 
in significant decreased Treg numbers. Moreover, the remaining 
Treg were partly defective in TGFβ secretion and were affected in 
IP-10 signaling.
Although the exact molecular mechanism are not clear 
yet, evidence exists that p38 expression in DCs is crucial for 
regulating their Treg-activating and/or Treg-converting func-
tions (42, 43). Therefore, small molecules tampering with p38 
pathways activation in DCs may be useful to shift the Treg–Th17 
balance in vivo.
Vice versa, in Treg expression of SOCS-1 (44), TRAF6 (45) 
and other transcriptions factors, such as Runx1, CNS2, and Cbfβ 
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(46) is important for maintenance of their suppressive phenotype, 
because absence of these factors in murine knock out models 
resulted in increased conversion of Treg into Th17-like cells. Thus, 
future investigations have to address as to how DC subsets and/
or surface molecules thereof interfere and trigger those signaling 
pathways in Treg.
In aggregate, these findings indicate that not only the genera-
tion of Treg but also their stability of phenotype is regulated by 
DCs. DC-derived cytokines, such as IL-6 and IL-23, as well as 
surface molecules are important to regulate Treg conversion into 
Th17 cells and are able to shift the balance between effector and 
Treg toward an enhanced immune response.
EX VIVO MANiPULATiON OF DCs FOR 
THe iNDUCTiON OF TReG
Role of Cytokines
In line with the concept that immature DCs induce Treg and 
tolerance, attempts can be made to stabilize the immature DC 
phenotype by manipulation of the cytokine environment. One 
important cytokine in this context is interleukin (IL)-10. After 
exposure of DCs to IL-10 in vitro culture systems, the cells display 
reduced surface expression of MHC class I and II molecules and 
reduced expression of T cell costimulatory molecules of the B7 
family as compared to their untreated counterparts. But not only 
surface molecules change, also the release of proinflammatory 
cytokines, i.e., IL-1β, IL-6, and TNFα and most markedly IL-12, is 
abolished after IL-10 treatment (47). However, all of these effects 
could only be induced in immature DCs. In contrast, mature 
DCs are insensitive to IL-10 and display a stable phenotype in the 
presence of IL-10. Therefore, for therapeutically use, IL-10 has to 
be added to in vitro culture systems very early on and/or in vivo 
elevated IL-10 levels have to be present once pre-DC are present in 
the respective tissues. The proof that those immature DCs do not 
only possess weak proinflammatory properties but also actively 
induce T cells with regulatory properties comes from observations 
in human melanoma. For example, IL-10 producing metastases are 
able to convert DCs into tolerogenic DC, which induce anergy in 
melanoma or alloantigen-specific CD4+ and CD8+ T cells (48, 49). 
But these anergic T cells were not just inactive, instead they acted 
as “bystander” suppressors that actively curbed anti-melanoma 
T cell activation (50). Moreover, in mice overexpressing IL-10, 
DCs displayed a remarkably immature phenotype (51) and the 
appearance of the immature DCs was accompanied by substan-
tially increased numbers of Treg in the spleens of these mice. This 
suggests that IL-10 plays an important role in rendering DCs not 
merely immature but also modifies their ability to induce Treg 
in vivo. To exploit the effects of IL-10 on DCs for Treg induction, 
IL-10 modulated DCs were injected in the murine model for EAE 
and in a GVHD model. In both instances, substantial amelioration 
of the disease and immune suppression by regulatory active T cells 
was observed (49, 52). Likewise, in a mouse model of asthma, the 
injection of IL-10-treated DCs lead to increased differentiation of 
bona fide Treg from effector T cells, which were able to ameliorate 
asthmatic incidence in house dust mite allergic mice (53, 54). Thus, 
these data establish IL-10 as a critical agent for induction of a Treg-
inducing DC phenotype. But moreover, IL-10 may also facilitate 
the cross talk between Treg and DCs, since it acts simultaneously 
on both cell types. For example, Misra et al. (55) have shown that 
DCs cocultured with Treg remain in an immature state as judged 
by surface marker expression. These “Treg-exposed” DCs were 
inferior in induction of T cell proliferation and produced significant 
amounts of IL-10, which (i) maintains Treg function in a paracrine 
fashion and (ii) keeps DCs immature via an autocrine loop.
Role of vitamin D3
Beyond the IL-10 effects, also non-cytokine immune modulators 
are active in keeping DCs functional as “Treg-inducers.” For 
instance, vitamin D [VitD3: 1,25(OH)2D3] treated DCs display a 
rather immature phenotype as they express low MHC class II, low 
amounts of T cell costimulatory molecules, and high production 
of IL-10 (56). This clearly tolerogenic phenotype of DC exert their 
immune regulatory functions by different means. First, it has been 
shown that VitD3 DCs are inactive in priming CD4+ and CD8+ 
T cells. Second, they are inducers of apoptosis in effector T cells 
and thirdly they are able to induce allo- and autoantigen-specific 
Treg from naïve CD4+ T cells, which were able to block diabetes 
in a non-obese diabetes animal model (57–59).
In case of VitD3 DCs, TNF-α plays a critical role as co-inducer 
of Treg. Although TNFα has a long standing track record for 
being proinflammatory, it has been shown to act tolerogenic 
on DCs. First observations by Menges et al. showed that TNFα 
matured DC are able to ameliorate multiple sclerosis symptoms in 
a murine EAE model (60). Further observations with human cells 
broadened these findings, by showing that VitD3 increased the 
amounts of membrane-bound TNFα in DCs and that in particular, 
this membrane-bound TNFα is critical for the induction of Treg 
(53). In addition to VitD3 alone, DCs have also been treated in 
combination with Dexamethason. These combinatorially treated 
DCs exhibited a more stable tolerogenic phenotype in vivo and 
were more potent in inducing Treg in a murine colitis model (61).
CONCLUSiON
In summary, these data show that agents, which actively block 
DC maturation, augment the ability of the DCs to induce 
Treg. Therefore, the “default” function of immature DCs is 
to maintain sufficient numbers of Treg in the periphery of the 
body. Prevention of DC maturation as well as antigen loading of 
otherwise untouched steady-state DCs in vivo may therefore be 
one future therapeutic approach to induce long-lasting tolerance 
in different autoimmune diseases.
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